Table 6.

The aPLs’ correlations in primary APS.

	aCL IgG	aCL IgM	aβ2GPI IgG	aβ2GPI IgM	aPE IgG	aPE IgM	aPS IgG	aPS IgM	aPT IgG	aPT IgM
aCL IgG	1	0.26	0.64 **	0.21	0.62 **	0.54 **	0.76 **	0.51 **	0.25	0.14
aCL IgM	0.26	1	0.31	0.69 **	0.46 **	0.54 **	0.46 **	0.81 **	0.38 *	0.53 **
aβ2GPI IgG	0.64 **	0.31	1	0.26	0.54 **	0.50 **	0.51 **	0.41 *	0.27	0.31
aβ2GPI IgM	0.21	0.69 **	0.26	1	0.56 **	0.56 **	0.39 *	0.61 **	0.55 **	0.55 **
aPE IgG	0.62 **	0.46 **	0.54 **	0.56 **	1	0.77 **	0.71 **	0.57 **	0.63 **	0.40 *
aPE IgM	0.54 **	0.54 **	0.50 **	0.56 **	0.77 **	1	0.56 **	0.67 **	0.50 **	0.51 **
aPS IgG	0.76 **	0.46 **	0.51 **	0.39 *	0.71 **	0.56 **	1	0.67 **	0.40 *	0.26
aPS IgM	0.51 **	0.81 **	0.41 *	0.61 **	0.57 **	0.67 **	0.67 **	1	0.39 *	0.54 **
aPT IgG	0.25	0.38 *	0.27	0.55 **	0.63 **	0.50 **	0.40 *	0.39 *	1	0.48 **
aPT IgM	0.14	0.53 **	0.31	0.55 **	0.40 *	0.51 **	0.26	0.54 **	0.48 **	1

APS—antiphospholipid syndrome; aPLs—antiphospholipid antibodies; aCL—anti-cardiolipin antibodies; aβ2GPI—anti-β2 glycoprotein I antibodies; aPE—anti-phosphatidylethanolamine antibodies; aPS—anti-phosphatidylserine antibodies; aPT—anti-prothrombin antibodies; Ig—immunoglobulin; * p < 0.05; ** p < 0.01.